Sanara MedTech clarifies Q2 sales per facility grew YoY but declined QoQ

Sanara MedTech Inc.

On Aug 15, 2023 earnings call, Sanara MedTech said sales per facility were growing; today's 8-K clarifies it was YoY, not QoQ.
Sequentially (Q2 2023 vs Q1 2023), sales per facility slightly declined.
Metric calculated as monthly Surgical Products sales divided by number of facilities with revenue; quarterly is average of monthly.
Surgical Products include CellerateRX, FORTIFY TRG, FORTIFY FLOWABLE, TEXAGEN, BiFORM, AMPLIFY, ALLOCYTE.
Correction filed under Regulation FD to avoid misleading investors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.